Kiniksa Pharmaceuticals (KNSA) Competitors $19.28 -0.42 (-2.13%) Closing price 04:00 PM EasternExtended Trading$19.29 +0.01 (+0.05%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KNSA vs. AXSM, TGTX, VRNA, KRYS, GRFS, RARE, ADMA, PTCT, OGN, and BHVNShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Verona Pharma (VRNA), Krystal Biotech (KRYS), Grifols (GRFS), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Organon & Co. (OGN), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. Axsome Therapeutics TG Therapeutics Verona Pharma Krystal Biotech Grifols Ultragenyx Pharmaceutical ADMA Biologics PTC Therapeutics Organon & Co. Biohaven Axsome Therapeutics (NASDAQ:AXSM) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings. Do analysts prefer AXSM or KNSA? Axsome Therapeutics presently has a consensus target price of $147.13, suggesting a potential upside of 12.04%. Kiniksa Pharmaceuticals has a consensus target price of $36.60, suggesting a potential upside of 89.59%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AXSM or KNSA more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Axsome Therapeutics' net margin of -91.87%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-91.87% -158.36% -37.46% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Which has better earnings & valuation, AXSM or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$270.60M23.52-$239.24M-$6.53-20.11Kiniksa Pharmaceuticals$384.10M3.63$14.08M-$0.14-137.89 Does the media prefer AXSM or KNSA? In the previous week, Axsome Therapeutics had 35 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 38 mentions for Axsome Therapeutics and 3 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.78 beat Axsome Therapeutics' score of 0.72 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 12 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, AXSM or KNSA? Axsome Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Do institutionals and insiders believe in AXSM or KNSA? 81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor AXSM or KNSA? Axsome Therapeutics received 293 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 69.98% of users gave Axsome Therapeutics an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAxsome TherapeuticsOutperform Votes46469.98% Underperform Votes19930.02% Kiniksa PharmaceuticalsOutperform Votes17165.02% Underperform Votes9234.98% SummaryKiniksa Pharmaceuticals beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$6.89B$5.68B$9.05BDividend YieldN/A2.91%5.32%4.00%P/E Ratio-138.709.4089.8519.33Price / Sales3.63310.651,031.7775.54Price / CashN/A75.4646.0938.87Price / Book3.105.525.065.00Net Income$14.08M$123.50M$113.46M$222.83M7 Day Performance-1.66%-4.27%-1.31%-0.56%1 Month Performance-3.14%-1.82%3.87%3.00%1 Year Performance-6.06%2.00%21.17%17.91% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals3.6519 of 5 stars$19.28-2.1%$36.60+89.8%-2.9%$1.39B$384.10M-137.70220Gap DownAXSMAxsome Therapeutics4.457 of 5 stars$107.43+0.9%$134.00+24.7%+36.4%$5.21B$270.60M-16.45380Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageTGTXTG Therapeutics4.403 of 5 stars$31.48-0.7%$40.67+29.2%+111.1%$4.90B$233.66M-314.77290VRNAVerona Pharma2.0085 of 5 stars$58.98+2.9%$53.14-9.9%+248.8%$4.74B$5.62M-30.7230Analyst ForecastPositive NewsKRYSKrystal Biotech4.8532 of 5 stars$159.03-0.4%$206.67+30.0%+34.6%$4.57B$50.70M89.85210Short Interest ↓GRFSGrifols2.1787 of 5 stars$6.62-3.9%N/A-13.2%$4.55B$7.13B0.0023,737Analyst ForecastShort Interest ↓Gap DownRAREUltragenyx Pharmaceutical4.6034 of 5 stars$43.42+0.9%$92.43+112.9%-6.7%$4.01B$434.25M-6.711,276Positive NewsADMAADMA Biologics4.1252 of 5 stars$16.47+2.0%$21.25+29.0%+203.1%$3.89B$258.21M58.82530Gap DownPTCTPTC Therapeutics3.5578 of 5 stars$50.01+9.0%$57.85+15.7%+90.6%$3.86B$937.82M-8.421,410Analyst ForecastGap DownOGNOrganon & Co.4.8115 of 5 stars$14.94-4.0%$21.33+42.8%-8.7%$3.85B$6.26B2.9610,000Upcoming EarningsBHVNBiohaven3.6034 of 5 stars$37.82-1.1%$63.00+66.6%-12.1%$3.82BN/A-4.04239Analyst ForecastShort Interest ↓News CoverageGap Down Related Companies and Tools Related Companies Axsome Therapeutics Alternatives TG Therapeutics Alternatives Verona Pharma Alternatives Krystal Biotech Alternatives Grifols Alternatives Ultragenyx Pharmaceutical Alternatives ADMA Biologics Alternatives PTC Therapeutics Alternatives Organon & Co. Alternatives Biohaven Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KNSA) was last updated on 2/12/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored$589 billion wiped out overnightYou need to watch this before you invest another cent in AI. Because more than $589 billion was wiped out o...Porter & Company | SponsoredElon has entered the MarkBeat conversationSpivey's firm accurately warned of both the 2008 and 2020 stock market crashes and have charged institutional ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
